MIST
Price
$1.94
Change
+$0.02 (+1.04%)
Updated
Jul 3, 12:40 PM (EDT)
Capitalization
100.51M
34 days until earnings call
ZLDPF
Price
$57.75
Change
+$0.45 (+0.79%)
Updated
Jul 1 closing price
Capitalization
4.09B
Interact to see
Advertisement

MIST vs ZLDPF

Header iconMIST vs ZLDPF Comparison
Open Charts MIST vs ZLDPFBanner chart's image
Milestone Pharmaceuticals
Price$1.94
Change+$0.02 (+1.04%)
Volume$102
Capitalization100.51M
Zealand Pharma A/S
Price$57.75
Change+$0.45 (+0.79%)
Volume$741
Capitalization4.09B
MIST vs ZLDPF Comparison Chart in %
Loading...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MIST vs. ZLDPF commentary
Jul 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MIST is a StrongBuy and ZLDPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 03, 2025
Stock price -- (MIST: $1.91 vs. ZLDPF: $57.75)
Brand notoriety: MIST and ZLDPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MIST: 38% vs. ZLDPF: 89%
Market capitalization -- MIST: $100.51M vs. ZLDPF: $4.09B
MIST [@Biotechnology] is valued at $100.51M. ZLDPF’s [@Biotechnology] market capitalization is $4.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MIST’s FA Score shows that 0 FA rating(s) are green whileZLDPF’s FA Score has 1 green FA rating(s).

  • MIST’s FA Score: 0 green, 5 red.
  • ZLDPF’s FA Score: 1 green, 4 red.
According to our system of comparison, MIST is a better buy in the long-term than ZLDPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MIST’s TA Score shows that 4 TA indicator(s) are bullish while ZLDPF’s TA Score has 6 bullish TA indicator(s).

  • MIST’s TA Score: 4 bullish, 4 bearish.
  • ZLDPF’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, ZLDPF is a better buy in the short-term than MIST.

Price Growth

MIST (@Biotechnology) experienced а +1.32% price change this week, while ZLDPF (@Biotechnology) price change was +3.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.91%. For the same industry, the average monthly price growth was +33.07%, and the average quarterly price growth was +3.79%.

Reported Earning Dates

MIST is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+6.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLDPF($4.09B) has a higher market cap than MIST($101M). MIST YTD gains are higher at: -18.856 vs. ZLDPF (-43.581). MIST has higher annual earnings (EBITDA): -48.18M vs. ZLDPF (-1.13B). ZLDPF has more cash in the bank: 8.54B vs. MIST (56M). MIST has less debt than ZLDPF: MIST (55.6M) vs ZLDPF (395M). ZLDPF has higher revenues than MIST: ZLDPF (55.7M) vs MIST (0).
MISTZLDPFMIST / ZLDPF
Capitalization101M4.09B2%
EBITDA-48.18M-1.13B4%
Gain YTD-18.856-43.58143%
P/E RatioN/AN/A-
Revenue055.7M-
Total Cash56M8.54B1%
Total Debt55.6M395M14%
FUNDAMENTALS RATINGS
MIST vs ZLDPF: Fundamental Ratings
MIST
ZLDPF
OUTLOOK RATING
1..100
1268
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
10079
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
3690
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
858

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIST's Valuation (55) in the Pharmaceuticals Major industry is in the same range as ZLDPF (76) in the null industry. This means that MIST’s stock grew similarly to ZLDPF’s over the last 12 months.

ZLDPF's Profit vs Risk Rating (79) in the null industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that ZLDPF’s stock grew similarly to MIST’s over the last 12 months.

ZLDPF's SMR Rating (94) in the null industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that ZLDPF’s stock grew similarly to MIST’s over the last 12 months.

MIST's Price Growth Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZLDPF (90) in the null industry. This means that MIST’s stock grew somewhat faster than ZLDPF’s over the last 12 months.

ZLDPF's P/E Growth Rating (6) in the null industry is significantly better than the same rating for MIST (100) in the Pharmaceuticals Major industry. This means that ZLDPF’s stock grew significantly faster than MIST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MISTZLDPF
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
59%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
69%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
47%
Advances
ODDS (%)
Bullish Trend 8 days ago
82%
Bullish Trend 3 days ago
72%
Declines
ODDS (%)
Bearish Trend 14 days ago
84%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CAFEX41.290.17
+0.41%
American Funds AMCAP 529E
EPLKX21.450.04
+0.19%
NYLI Epoch U.S. Equity Yield Class C
FDTCX31.87N/A
N/A
Fidelity Advisor Diversified Stock C
MMFYX16.97N/A
N/A
MassMutual Equity Opports Svc
GGIAX13.42N/A
N/A
Goldman Sachs Global Infras A

MIST and

Correlation & Price change

A.I.dvisor tells us that MIST and AKBA have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MIST and AKBA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIST
1D Price
Change %
MIST100%
+1.86%
AKBA - MIST
33%
Poorly correlated
+1.40%
ETNB - MIST
32%
Poorly correlated
+3.80%
GYRE - MIST
29%
Poorly correlated
+4.56%
PRAX - MIST
29%
Poorly correlated
+7.30%
OSRH - MIST
29%
Poorly correlated
-7.25%
More

ZLDPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLDPF has been loosely correlated with KRYS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLDPF jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLDPF
1D Price
Change %
ZLDPF100%
N/A
KRYS - ZLDPF
46%
Loosely correlated
+1.69%
CLDX - ZLDPF
30%
Poorly correlated
+8.65%
NERV - ZLDPF
22%
Poorly correlated
+3.59%
SNDX - ZLDPF
22%
Poorly correlated
+2.04%
MIST - ZLDPF
22%
Poorly correlated
+1.86%
More